0000719135false00007191352023-11-092023-11-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

November 9, 2023

Date of Report (date of earliest event reported)
apyx8klogo.jpg
APYX MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
001-31885
11-2644611
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
5115 Ulmerton Road, Clearwater, Florida 33760
(Address of principal executive offices, zip code)
(727) 384-2323
(Issuer's telephone number)
_____________________________________________________________
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stockAPYXNasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


o



Item 2.02 - Results of Operations and Financial Condition

On November 9, 2023, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the third quarter ended September 30, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Such information, including the Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits
(d)



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 9, 2023Apyx Medical Corporation
By:/s/ Tara Semb
Tara Semb
Chief Financial Officer, Secretary and Treasurer

image3.jpg

EXHIBIT 99.1

Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook

Advanced Energy Sales increased 39% year-over-year in Q3

CLEARWATER, FL — November 9, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended September 30, 2023, and updated its financial expectations for the full year ending December 31, 2023.

Third Quarter 2023 Financial Summary:

•Total revenue of $12.0 million, up 31% year-over-year.
◦Advanced Energy revenue of $9.8 million, up 39% year-over-year.
◦OEM revenue of $2.1 million, up 5% year-over-year.
•Net loss attributable to stockholders of $4.6 million, down $1.1 million, or 20%, year-over-year.
•Adjusted EBITDA loss of $3.1 million, down $0.8 million, or 21%, year-over-year.

Highlights Subsequent to Quarter End

•On November 9, 2023, the Company announced a new, five-year credit agreement with Perceptive Credit Holdings IV, LP (“Perceptive”), an affiliate of Perceptive Advisors. The credit agreement provides for a facility of up to $45.0 million consisting of senior, secured term loans. The Perceptive credit facility matures on November 8, 2028 and includes an initial loan of $37.5 million and a delayed draw loan of $7.5 million. The initial loan of $37.5 million was fully funded on November 8, 2023, with approximately $11.0 million of the proceeds used to satisfy all obligations under the Company’s MidCap credit agreement, as well as approximately $2.5 million of transaction fees and other expenses related to the transactions.
•On November 9, 2023, the Company and Tara Semb, Chief Financial Officer, announced that Ms. Semb would be leaving the Company in order to pursue other opportunities. Ms. Semb’s departure is not due to any disagreement with the Company on any matter, including matters related to the Company’s operations, policies, practices, financial reporting or controls. The Board of Directors initiated a formal search process which has resulted in the Company identifying her successor. Ms. Semb plans to continue in her position as Chief Financial Officer until her successor is formally appointed.

Management Comments:

“We delivered Advanced Energy revenue growth in the third quarter of 39% year-over-year, fueled primarily by global sales of our generators, which increased by more than 65% both in the U.S. and internationally, along with significant contributions from handpiece sales as well.” said Charlie Goodwin, President and Chief Executive Officer. “Our Advanced Energy sales performance benefited from multiple factors, including our recently obtained FDA 510(k) clearances for new clinical indications, the commercialization of our next-generation Apyx One Generator and strong demand from distributors in key geographic regions. We complemented our revenue performance with continued profitability improvements as well, reducing our net loss attributable to stockholders and adjusted EBITDA by 20% and 21% year-over-year, respectively.”

Mr. Goodwin continued: “Ultimately, we did not see the level of revenue performance in our Advanced Energy segment that we had anticipated in the third quarter. We believe this was due to a combination of factors, including stronger-than-anticipated seasonality, surgeon reticence to purchase capital equipment given the current financing environment and sales and marketing team execution that did not meet our expectations. Our updated guidance reflects both our third quarter results and our revised expectations for the balance of the year. We are committed to

image3.jpg
achieving our stated expectations for 2023 by executing our growth strategy in the fourth quarter, while continuing to leverage our recent progress in securing new 510(k) clearances, introducing new products and raising awareness of the safety and efficacy of our Renuvion technology for cosmetic procedures at both the surgeon and patient level. Subsequent to quarter end, we capitalized on the multiple regulatory, operating and commercial milestones achieved in 2023 to secure a new credit facility with Perceptive Advisors, providing us with additional capital – with more favorable terms overall than our prior agreement – which significantly strengthens our balance sheet and enhances our financial flexibility.”
2

image3.jpg

The following tables present revenue by reportable segment and geography:
Three Months Ended
September 30,		Increase/DecreaseNine Months Ended
September 30,		Increase/Decrease
(In thousands)20232022$ Change% Change20232022$ Change% Change
Advanced Energy$9,836 $7,080 $2,756 38.9 %$31,248 $26,258 $4,990 19.0 %
OEM2,140 2,034 106 5.2 %6,439 5,641 798 14.1 %
Total$11,976 $9,114 $2,862 31.4 %$37,687 $31,899 $5,788 18.1 %
Three Months Ended September 30,Increase/DecreaseNine Months Ended
September 30,		Increase/Decrease
(In thousands)20232022$ Change% Change20232022$ Change% Change
Domestic$8,652 $6,997 $1,655 23.7 %$27,660 $22,492 $5,168 23.0 %
International3,324 2,117 1,207 57.0 %10,027 9,407 620 6.6 %
Total$11,976 $9,114 $2,862 31.4 %$37,687 $31,899 $5,788 18.1 %

Third Quarter 2023 Results:

Total revenue for the three months ended September 30, 2023 increased $2.9 million, or 31% year-over-year, to $12.0 million, compared to $9.1 million in the prior year period. Advanced Energy segment sales increased $2.8 million, or 39% year-over-year, to $9.8 million. OEM segment sales increased $0.1 million, or 5% year-over-year to $2.1 million. The increase in Advanced Energy sales was primarily due to growth in domestic sales, which was driven by sales of the Company's recently launched Apyx One Console to both new and existing customers. Advanced Energy sales also benefited from growth in international generator and handpiece sales. The increase in OEM sales was due to increased sales volume to existing customers. For the third quarter of 2023, revenue in the United States increased $1.7 million, or 24% year-over-year, to $8.7 million, and international revenue increased $1.2 million, or 57% year-over-year, to $3.3 million.

Gross profit for the three months ended September 30, 2023, increased $2.2 million, or 39% year-over-year, to $8.0 million, compared to $5.8 million in the prior year period. Gross profit margin for the three months ended September 30, 2023, was 66.6%, compared to 63.2% in the prior year period. The increase in gross profit margins for the three months ended September 30, 2023 from the prior year period is primarily attributable to changes in the sales mix between the Company's two segments, with the Advanced Energy segment comprising a higher percentage of total sales and sales mix within our Advanced Energy segment. These increases were partially offset by geographic mix within the Advanced Energy segment, with international sales comprising a higher percentage of total sales, and by product mix.

Operating expenses for the three months ended September 30, 2023 increased $1.1 million, or 9% year-over-year, to $12.6 million, compared to $11.5 million in the prior year period. The year-over-year change in operating expenses was driven by a $0.8 million increase in salaries and related costs, a $0.2 million increase in selling, general and administrative expenses and a $0.2 million increase in research and development expenses. These increases were partially offset by a $0.1 million decrease in professional services.

Income tax (benefit) expense for the three months ended September 30, 2023 and 2022 was $(0.3) million and $0.1 million, respectively.

3

image3.jpg
Net loss attributable to stockholders for the three months ended September 30, 2023 was $4.6 million, or $0.13 per share, compared to $5.8 million, or $0.17 per share, in the prior year period.

Adjusted EBITDA loss for the three months ended September 30, 2023 and 2022 was approximately $3.1 million and $3.9 million, respectively.

First Nine Months of 2023 Results:

Total revenue for the nine months ended September 30, 2023, increased $5.8 million, or 18%, to $37.7 million, compared to $31.9 million in the prior year period. Advanced Energy segment sales increased $5.0 million, or 19% year-over-year, to $31.2 million, compared to $26.3 million in the prior year period. OEM segment sales increased $0.8 million, or 14% year-over-year, to $6.4 million, compared to $5.6 million in the prior year period. For the first nine months of 2023, revenue in the United States increased $5.2 million, or 23% year-over-year, to $27.7 million, and international revenue increased $0.6 million, or 7% year-over-year, to $10.0 million. The increase in Advanced Energy sales was driven by domestic sales of the Company’s recently launched Apyx One Console to both new and existing customers. The increase in OEM sales was due to increased sales volume to existing customers, as well as incremental new sales upon the commencement of the supply arrangement related to the completion of the development portion of some of the Company’s OEM development agreements.

Net loss attributable to stockholders for the nine months ended September 30, 2023 was $9.1 million, or $0.26 per share, compared to $17.1 million, or $0.50 per share, in the prior year period. Included in net loss for the nine months ended September 30, 2023 was a $2.7 million gain on the sale-leaseback of our Clearwater, FL facility.

Full Year 2023 Financial Outlook:

The Company is updating its financial guidance for the year ending December 31, 2023 to:

•Total revenue in the range of $53.0 million to $54.0 million, representing growth of approximately 19% to 21% year-over-year, compared to total revenue of $44.5 million for the year ended December 31, 2022. The Company’s prior guidance range for total revenue was $59.0 million to $62.0 million, representing growth of 33% to 39% year-over-year.
◦Total revenue guidance assumes:
▪Advanced Energy revenue in the range of $44.5 million to $45.5 million, representing growth of approximately 21% to 24% year-over-year, compared to Advanced Energy revenue of $36.8 million for the year ended December 31, 2022. The Company’s prior guidance range for Advanced Energy revenue was $51.0 million to $54.0 million, representing growth of 39% to 47% year-over-year.
▪OEM revenue of approximately $8.5 million, representing growth of approximately 10% year-over-year, compared to $7.7 million for the year ended December 31, 2022. The Company’s prior guidance for OEM revenue was $8.0 million, representing growth of 4% year-over-year.

•Net loss attributable to stockholders of approximately $16 million, compared to $23.2 million for the year ended December 31, 2022. The Company’s prior guidance for net loss attributable to stockholders was approximately $10.5 million.
4

image3.jpg
Conference Call Details:

Management will host a conference call at 8:00 a.m. Eastern Time on November 9, 2023 to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-8289 (or 201-689-8341 for international callers) and provide access code 13741467. Participants should ask for the Apyx Medical Corporation Call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and at:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=wXKixaYt

A telephonic replay will be available approximately three hours after the end of the call through the following two weeks. The replay can be accessed by dialing 877-660-6853 for U.S. callers or 201-612-7415 for international callers and using the replay access code: 13741467. The webcast will be archived on the Investor Relations section of the Company’s website.

Investor Relations Contact:

ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com


5

image3.jpg
About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; the impact of the March 14, 2022 FDA Safety Communication on our business and operations; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
6

image3.jpg
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)


Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Sales$11,976 $9,114 $37,687 $31,899 
Cost of sales3,998 3,357 12,857 11,009 
Gross profit7,978 5,757 24,830 20,890 
Other costs and expenses:
Research and development1,276 1,061 3,596 3,289 
Professional services1,831 1,936 5,165 6,611 
Salaries and related costs4,667 3,871 14,770 13,944 
Selling, general and administrative4,841 4,671 15,474 14,675 
Total other costs and expenses12,615 11,539 39,005 38,519 
   Gain on sale-leaseback— — 2,692 — 
Loss from operations(4,637)(5,782)(11,483)(17,629)
Interest income248 73 478 93 
Interest expense(585)(1)(1,362)(12)
Other (expense) income, net (19)(35)622 551 
Total other (expense) income, net(356)37 (262)632 
Loss before income taxes(4,993)(5,745)(11,745)(16,997)
Income tax (benefit) expense(318)50 (2,519)216 
Net loss(4,675)(5,795)(9,226)(17,213)
   Net loss attributable to non-controlling interest
(46)(31)(120)(78)
Net loss attributable to stockholders$(4,629)$(5,764)$(9,106)$(17,135)
Loss per share:
Basic and Diluted$(0.13)$(0.17)$(0.26)$(0.50)
Weighted average number of shares outstanding - basic and diluted34,64234,56934,61434,488


7

image3.jpg
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
September 30, 2023
(Unaudited)		December 31,
2022
ASSETS
Current assets:
Cash and cash equivalents$22,134 $10,192 
Trade accounts receivable, net of allowance of $652 and $66812,648 10,602 
Income tax receivables— 7,545 
Other receivables596 99 
Inventories, net of provision for obsolescence of $611 and $45711,285 11,797 
Prepaid expenses and other current assets3,487 2,737 
Total current assets50,150 42,972 
Property and equipment, net2,093 6,761 
Operating lease right-of-use assets5,274 710 
Finance lease right-of-use assets74 115 
Other assets1,855 1,217 
Total assets$59,446 $51,775 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$2,050 $2,669 
Accrued expenses and other liabilities7,914 8,928 
Current portion of operating lease liabilities310 216 
Current portion of finance lease liabilities20 37 
Total current liabilities10,294 11,850 
Term loan, net9,009 — 
Long-term operating lease liabilities4,992 470 
Long-term finance lease liabilities58 73 
Long-term contract liabilities1,326 1,408 
Other liabilities181 181 
Total liabilities25,860 13,982 
EQUITY
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2023 and December 31, 2022— — 
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,855 issued and outstanding as of September 30, 2023 and 34,597,822 issued and outstanding as of December 31, 202235 35 
Additional paid-in capital78,154 73,282 
Accumulated deficit(44,841)(35,735)
Total stockholders' equity33,348 37,582 
Non-controlling interest238 211 
Total equity33,586 37,793 
Total liabilities and equity$59,446 $51,775 

8

image3.jpg
APYX MEDICAL CORPORATION
RECONCILIATION OF GAAP NET LOSS RESULTS TO NON-GAAP ADJUSTED EBITDA
(Unaudited)
Use of Non-GAAP Financial Measure

We present the following non-GAAP measure because we believe such measure is a useful indicator of our operating performance. Our management uses this non-GAAP measure principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.

The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net income (loss) attributable to stockholders (GAAP) plus income tax expense (benefit), interest, depreciation and amortization, stock-based compensation expense and other significant non-recurring items.
(In thousands)Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Net loss attributable to stockholders$(4,629)$(5,764)$(9,106)$(17,135)
Interest income(248)(73)(478)(93)
Interest expense585 1 1,362 12 
Income tax (benefit) expense(318)50 (2,519)216 
Depreciation and amortization186 216 540 688 
Stock based compensation1,351 1,692 4,200 5,056 
Gain on sale-leaseback— — (2,692)— 
Adjusted EBITDA$(3,073)$(3,878)$(8,693)$(11,256)

9

v3.23.3
Cover Page
Nov. 09, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 09, 2023
Entity Registrant Name APYX MEDICAL CORP
Entity Address, Address Line One 5115 Ulmerton Road
Entity Address, City or Town Clearwater
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33760
City Area Code 727
Local Phone Number 384-2323
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity File Number 001-31885
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 11-2644611
Title of 12(b) Security Class A common stock
Trading Symbol APYX
Security Exchange Name NASDAQ
Entity Central Index Key 0000719135
Amendment Flag false
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Apyx Medical Charts.
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Apyx Medical Charts.